Intelligent Bio Solutions Inc. (NASDAQ:INBS) Sees Large Drop in Short Interest

Posted by George Bondi on Sep 13th, 2026

Intelligent Bio Solutions Inc. (NASDAQ:INBS – Get Free Report) was the target of a large decline in short interest in August. As of August 31st, there was short interest totaling 33,673 shares, a decline of 68.0% from the August 15th total of 105,073 shares. Based on an average daily volume of 90,645 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.1% of the shares of the stock are short sold.

Intelligent Bio Solutions Price Performance

NASDAQ INBS traded down $0.06 on Friday, hitting $2.13. 30,088 shares of the stock were exchanged, compared to its average volume of 336,077. Intelligent Bio Solutions has a 52-week low of $1.52 and a 52-week high of $24.90. The company has a market capitalization of $6.45 million, a price-to-earnings ratio of -0.24 and a beta of 4.25. The company’s 50-day moving average price is $2.20 and its two-hundred day moving average price is $2.70.

Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) last released its earnings results on Wednesday, August 19th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.68. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $1.22 million. Intelligent Bio Solutions had a negative return on equity of 175.35% and a negative net margin of 294.88%. Equities analysts predict that Intelligent Bio Solutions will post -5.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

INBS has been the subject of a number of research reports. Zacks Research upgraded shares of Intelligent Bio Solutions to a “hold” rating in a report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intelligent Bio Solutions in a report on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Intelligent Bio Solutions presently has an average rating of “Reduce”.

Check Out Our Latest Report on Intelligent Bio Solutions

Institutional Investors Weigh In On Intelligent Bio Solutions

An institutional investor recently raised its position in Intelligent Bio Solutions stock. Alyeska Investment Group L.P. raised its holdings in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS – Free Report) by 9.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 673,492 shares of the company’s stock after acquiring an additional 59,600 shares during the quarter. Alyeska Investment Group L.P. owned approximately 7.12% of Intelligent Bio Solutions worth $687,000 at the end of the most recent quarter. 32.97% of the stock is owned by hedge funds and other institutional investors.

Intelligent Bio Solutions Company Profile

(Get Free Report)

Intelligent Bio Solutions, Inc, through its wholly owned subsidiary, is focused on the design, development and marketing of rapid, real-time detection and identification systems for foodborne and environmental pathogens. The company’s flagship product, the RAPID-B System, integrates patented biosensor and fluorescence technologies to detect viable microorganisms in a fraction of the time required by traditional culture-based testing methods. This approach enables food processors, beverage producers, environmental testing laboratories and homeland security agencies to identify contaminants such as Escherichia coli O157:H7, Salmonella spp.